PMID- 37759823
OWN - NLM
STAT- MEDLINE
DCOM- 20230929
LR  - 20231003
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 13
IP  - 9
DP  - 2023 Sep 20
TI  - An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in 
      Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials.
LID - 10.3390/biom13091422 [doi]
LID - 1422
AB  - Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the 
      treatment of hormone receptor-positive (HR+) and human epidermal growth factor 
      receptor 2-negative (HER2-) breast cancer over the last decade. These inhibitors 
      are currently established as first- and second-line systemic treatment choices 
      for both endocrine-sensitive and -resistant breast cancer populations alongside 
      endocrine therapy (ET) or monotherapy. Data on targeted therapy continue to 
      mature, and the number of publications has been constantly rising. Although these 
      drugs have been demonstrated to prolong overall survival (as well as 
      progression-free survival (PFS) in breast cancer patients), changing the paradigm 
      of all current knowledge, they also cause important adverse events (AEs). This 
      review provides the latest summary and update on the safety profile of the three 
      CDK4/6 inhibitors, as it appears from all major phase II and III randomized 
      clinical trials regarding palbociclib, ribociclib, and abemaciclib, including the 
      most relevant 15 clinical trials.
FAU - Stanciu, Ioana-Miruna
AU  - Stanciu IM
AUID- ORCID: 0009-0003-5937-0778
AD  - Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 
      020021 Bucharest, Romania.
AD  - Department of Medical Oncology, Elias University Emergency Hospital, 011461 
      Bucharest, Romania.
FAU - Parosanu, Andreea Ioana
AU  - Parosanu AI
AD  - Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 
      020021 Bucharest, Romania.
AD  - Department of Medical Oncology, Elias University Emergency Hospital, 011461 
      Bucharest, Romania.
FAU - Nitipir, Cornelia
AU  - Nitipir C
AD  - Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 
      020021 Bucharest, Romania.
AD  - Department of Medical Oncology, Elias University Emergency Hospital, 011461 
      Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20230920
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - EC 2.7.11.22 (CDK4 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/drug therapy
MH  - Progression-Free Survival
MH  - Cyclin-Dependent Kinase 4
MH  - Clinical Trials, Phase II as Topic
PMC - PMC10526227
OTO - NOTNLM
OT  - CDK4/6 inhibitor toxicities
OT  - abemaciclib
OT  - breast cancer
OT  - palbociclib
OT  - ribociclib
OT  - safety profile
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/28 06:43
MHDA- 2023/09/29 06:44
PMCR- 2023/09/20
CRDT- 2023/09/28 01:03
PHST- 2023/08/15 00:00 [received]
PHST- 2023/09/15 00:00 [revised]
PHST- 2023/09/19 00:00 [accepted]
PHST- 2023/09/29 06:44 [medline]
PHST- 2023/09/28 06:43 [pubmed]
PHST- 2023/09/28 01:03 [entrez]
PHST- 2023/09/20 00:00 [pmc-release]
AID - biom13091422 [pii]
AID - biomolecules-13-01422 [pii]
AID - 10.3390/biom13091422 [doi]
PST - epublish
SO  - Biomolecules. 2023 Sep 20;13(9):1422. doi: 10.3390/biom13091422.